Filgotinib demonstrates sustained efficacy and safety in long-term rheumatoid arthritis study

by

In a significant development for rheumatoid arthritis (RA) management, interim results from the long-term FINCH 4 extension study published in Rheumatic and Musculoskeletal Diseases Open have shown that filgotinib, a Janus kinase (JAK) 1-preferential inhibitor, maintains efficacy and a consistent safety profile over 156 weeks. This marks a promising step forward in achieving sustained disease control for patients with moderate-to-severe RA. 

Filgotinib was evaluated in two doses, 200 mg, and 100 mg, among patients continuing from the FINCH 1, 2, and 3 studies or receiving the treatment de novo. The results were encouraging across all treatment groups. For patients transitioning from prior studies, 67.3% of those on filgotinib 200 mg and 59.5% on 100 mg achieved an American College of Rheumatology 20% response (ACR20)  response by week 156. Among de novo patients, ACR20 was observed in 60.2% of those on 200 mg and 54.6% on 100 mg. Importantly, Boolean remission 1.0 was reached by 18.8% of de novo patients on 200 mg and 15.4% on 100 mg. For those continuing treatment, Boolean remission 1.0 rates were slightly higher at 21.1% and 18.5%, respectively, under the less stringent Boolean 2.0 criteria. 

Efficacy was consistent regardless of whether patients had an inadequate response to methotrexate or participated in earlier FINCH trials, reinforcing the robustness of filgotinib’s long-term benefits. Safety data from FINCH 4 aligned with the known safety profile of filgotinib, with no unexpected adverse events reported. This consistency supports its viability as a long-term therapeutic option for RA management. 

Filgotinib is an oral medication that selectively inhibits JAK-1. By targeting JAK1, it modulates a specific subset of proinflammatory cytokines within the JAK–signal transducer and activator of transcription pathway, distinct from those influenced by JAK2 or JAK3 inhibition. Following oral administration, filgotinib is extensively and rapidly absorbed. It is primarily metabolized by carboxylesterase isoform 2 into its main active metabolite, GS-829845. This metabolite retains a similar JAK1 selectivity but exhibits 10-fold lower activity and approximately 16- to 20-fold higher systemic exposure compared to the parent compound. Filgotinib was assessed in the FINCH 1–3 trials, a series of phase 3 randomized controlled studies. These trials included methotrexate-naïve patients (FINCH 3) and those with inadequate responses to methotrexate (FINCH 1) or biologic disease-modifying antirheumatic drugs (bDMARDs; FINCH 2). Each study achieved its primary endpoint, demonstrating that a significantly higher proportion of patients receiving filgotinib reached the American College of Rheumatology 20% response (ACR20) compared to those receiving placebo at week 12 (FINCH 1 and FINCH 2) or methotrexate at week 24 (FINCH 3). 

The findings underscore the potential of JAK inhibitors like filgotinib to achieve durable disease control in patients who may not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). As the FINCH 4 study continues, these interim results highlight the importance of sustained, targeted therapies in improving outcomes for individuals living with RA. These findings offer clinicians robust evidence supporting the sustained long-term clinical benefits of filgotinib for patients with RA. 

References 

  1. Buch MH, Aletaha D, Combe BG, Tanaka Y, Caporali R, Schulze-Koops H, et al. Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study. RMD Open. 2024 Oct 24;10(4):e004476.  
  2. Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet. 2022 Jun;61(6):819-832. 

 

Â